ITGA9

Chr 3

integrin subunit alpha 9

Also known as: ALPHA-RLC, ITGA4L, RLC

The protein forms an integrin receptor (alpha-9/beta-1) that mediates cell adhesion by binding to VCAM1, cytotactin, and osteopontin, and regulates vascular smooth muscle contraction by inhibiting calcium influx. Mutations cause autosomal recessive muscular dystrophy-limb girdle type 2S, which presents with progressive proximal muscle weakness and elevated creatine kinase levels. The gene is highly constrained against loss-of-function variants (LOEUF 0.42), indicating intolerance to protein-disrupting mutations.

OMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 0.42
Clinical SummaryITGA9
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.27) despite low pLI — interpret in context.
📋
ClinVar Variants
12 unique Pathogenic / Likely Pathogenic· 148 VUS of 217 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.42LOEUF
pLI 0.008
Z-score 4.99
OE 0.27 (0.180.42)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
0.63Z-score
OE missense 0.93 (0.860.99)
532 obs / 574.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.27 (0.180.42)
00.351.4
Missense OE0.93 (0.860.99)
00.61.4
Synonymous OE1.08
01.21.6
LoF obs/exp: 15 / 54.9Missense obs/exp: 532 / 574.3Syn Z: -1.00
DN
0.6743th %ile
GOF
0.6442th %ile
LOF
0.3067th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

217 submitted variants in ClinVar

Classification Summary

Pathogenic11
Likely Pathogenic1
VUS148
Likely Benign22
Benign19
11
Pathogenic
1
Likely Pathogenic
148
VUS
22
Likely Benign
19
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
11
0
11
Likely Pathogenic
0
0
1
0
1
VUS
0
136
12
0
148
Likely Benign
0
7
5
10
22
Benign
0
5
6
8
19
Total01483518201

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ITGA9 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →